Spravato — esketamine nasal
Named-patient access overview. Spravato is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Spravato
Spravato (esketamine nasal) is manufactured by Janssen (J&J) and indicated for Treatment-resistant depression — OUT OF SCOPE (esketamine, DEA Schedule III + REMS in-clinic only; PlatformCo does not handle controlled substances. Also practically infeasible given REMS site-of-care restriction.). It is a unverified approved by the US FDA in unverified and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Spravato
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Spravato for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Spravato is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Spravato in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Start a request for Spravato
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.